Today: 8 February 2026
Subscribe
Browse Category

LSE:HLN News 4 December 2025 - 6 February 2026

Haleon shares close higher in London as investors turn to Feb. 25 results

Haleon shares close higher in London as investors turn to Feb. 25 results

Haleon shares rose 2% to 379 pence Friday, outperforming the London market as the FTSE 100 logged a seventh straight monthly gain. About 14.1 million Haleon shares traded between 371.1 and 379.3 pence. The company will report full-year results on Feb. 25 and plans a major operating overhaul, including a new chief growth officer. GSK also gained 1.3% in London trading.
31 January 2026
·
Haleon share price slips in London as investors wait for the next big update

Haleon share price slips in London as investors wait for the next big update

Haleon shares dipped 0.1% to 361.8 pence in early London trading Friday after a 1.1% drop Thursday, with about 1 million shares changing hands. The move follows a recent reorganisation announcement as investors await full-year results on Feb. 25. European stocks also edged lower, pressured by a 1% decline in mining shares. Haleon has not issued new regulatory news since early January.
16 January 2026
·
Haleon stock today: shares slip as JD Health China deal lands and Deutsche Bank turns bearish

Haleon stock today: shares slip as JD Health China deal lands and Deutsche Bank turns bearish

Haleon shares fell 0.5% to 364.5 pence in early London trading after Deutsche Bank downgraded the stock to “sell” and cut its price target to 340 pence. JD Health and Haleon announced a new deal to expand their partnership in China beyond chronic disease management. Investors await Haleon’s full-year results on Feb. 25. Financial terms of the China deal were not disclosed.
15 January 2026
·
Haleon PLC stock slides on operating model shake-up as investors look to Feb. 25 results

Haleon PLC stock slides on operating model shake-up as investors look to Feb. 25 results

Haleon shares fell 1.18% to 367.50p Friday after announcing a major operating overhaul, splitting its EMEA and Latin America regions and creating a standalone India Subcontinent unit. New senior roles include Filippo Lanzi as Chief Growth Officer and Björn Timelin as Chief Transformation Officer. The changes are set for mid-2026. Haleon’s market value stands at about £32.7 billion.
10 January 2026
··
Haleon PLC stock edges lower after executive share-deal filing, with earnings in focus

Haleon PLC stock edges lower after executive share-deal filing, with earnings in focus

Haleon shares fell 0.4% to 375.2 pence in early London trading after two senior executives disclosed small share purchases under the company’s reward plan. The transactions, involving 34 partnership shares each by the general counsel and chief marketing officer, were filed Tuesday. Investors are now looking ahead to Haleon’s full-year results and 2026 guidance on Feb. 25.
7 January 2026
··
Haleon PLC (HLN) News Today, 17 December 2025: Shares Rise as Investors Digest Morgan Stanley “Top Pick” Call and Incoming Board Changes

Haleon PLC (HLN) News Today, 17 December 2025: Shares Rise as Investors Digest Morgan Stanley “Top Pick” Call and Incoming Board Changes

Haleon PLC (LSE/NYSE: HLN) closed higher on 17 December 2025, rebounding after Tuesday’s dip. Here’s what’s moving the consumer-health giant behind Sensodyne, Panadol and Advil, including a Morgan Stanley upgrade, leadership changes effective 1 January 2026, and the next key date on the company calendar. Haleon PLC (HLN), the consumer health company behind household brands such as Sensodyne, Panadol, Advil, Centrum, Voltaren and Theraflu, ended Wednesday’s session higher in London, as investors balanced near-term market noise against a string of “positioning” catalysts that have kept the stock in focus into year-end. London South East+2Hargreaves Lansdown+2 While there was no new
17 December 2025
·
Haleon PLC (HLN) Stock on December 4, 2025: Price, Latest News, Analyst Targets and 2026 Outlook

Haleon PLC (HLN) Stock on December 4, 2025: Price, Latest News, Analyst Targets and 2026 Outlook

Updated: December 4, 2025 Haleon PLC – the consumer‑health group behind Sensodyne, Voltaren, Advil, Panadol and Centrum – is ending 2025 in a strangely paradoxical place: the business is grinding out steady growth and strong cash flow, while the share price has been drifting lower in recent weeks. As of early trading on December 4, 2025, Haleon’s New York‑listed ADR (NYSE: HLN) is changing hands around $9.5 per share, implying a market cap in the mid‑$40 billion range. MarketBeat On the London Stock Exchange (LSE: HLN), the stock closed at £3.61 on Wednesday, December 3, down 2.09% on the day
4 December 2025
·

Stock Market Today

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

Longsys Electronics stock heads into Monday after new guarantees; what 301308 investors watch next

8 February 2026
Shanghai, Feb 8, 2026, 10:25 CST — Market closed Shenzhen Longsys Electronics Co., Ltd.’s Class A shares head into Monday’s reopen after the memory products maker flagged new guarantees for overseas units in a late-Friday filing. It is not an earnings update. But it lands on a market that has started to look harder at cash needs, debt and offshore exposure across China’s fast-rerating chip names. For Longsys, the timing matters because the filing highlights how much of the group’s funding is still supported by parent-company guarantees, even as it runs procurement and manufacturing footprints outside mainland China. In the
MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

MACOM stock price steadies near highs into Monday after earnings pop and fresh filings

8 February 2026
MACOM shares rose 3.5% to $235.87 Friday after the company reported fiscal Q1 revenue of $271.6 million and raised its full-year data center growth outlook to 35–40%. Fidelity’s FMR LLC disclosed a 10.7% stake, while shareholder Susan Ocampo filed to potentially sell up to 100,000 shares. Stifel raised its price target to $255. MACOM expects to repay $161 million in convertible notes in March.
Go toTop